WEBULL

Orion Oyj (HLSE:ORNBV) Stock Q2 Margin Strength Tests Cautious Growth Narratives

Simply Wall St · 2d ago

Orion Oyj (HLSE:ORNBV) has put solid numbers on the table for Q2 2026, with revenue of €521.6 million and basic EPS of €1, while trailing twelve month EPS stands at €4.17 on revenue of €2.1 billion. The company has seen quarterly revenue move from €416.5 million in Q2 2025 to €521.6 million in Q2 2026, with basic EPS over that stretch ranging from €0.59 to €1.85. This sets up a story that now hinges on a trailing net profit margin of 28.5% and how durable that profitability looks from here.

See our full analysis for Orion Oyj.

With the headline figures in place, the next step is to see how these margins and growth trends line up with the prevailing narratives around Orion Oyj’s earnings strength and long term outlook.

See what the community is saying about Orion Oyj

HLSE:ORNBV Revenue & Expenses Breakdown as at Jul 2026
HLSE:ORNBV Revenue & Expenses Breakdown as at Jul 2026

28.5% margin and €587.1 million trailing profit

  • On a trailing basis, Orion Oyj has €2.1b in revenue and €587.1 million in net income excluding extra items, which translates into a 28.5% net profit margin compared with 22.5% a year earlier.
  • Supporters of the bullish narrative point to this high margin and earnings growth as a sign that Orion’s oncology push can support earnings quality. However:
    • Trailing earnings growth of 55.3% over the last year and a 5‑year earnings growth rate of 18.9% sit alongside plans to increase R&D and sales and marketing spending, so higher costs could offset some of that strength.
    • The bullish view leans heavily on oncology projects such as Phase III and Phase II programs, but the data also show earlier pipeline setbacks like ODM 105, which illustrates that not every trial converts into future profit.

Supporters who focus on Orion Oyj’s margin strength and pipeline potential often stop at the headline numbers, but the detailed bull case goes much further into products, trials and timelines, which you can review in the dedicated narrative 🐂 Orion Oyj Bull Case

P/E of 18.6x and €77.40 vs €74.33 target

  • Orion Oyj trades at €77.40 with a trailing P/E of 18.6x, compared with a European Pharmaceuticals industry average of 21x and a peer average of 50.1x, while analysts’ consensus price target stands at €74.33.
  • Critics in the bearish narrative argue that growth may not fully support rich valuation multiples, and the figures give you a mixed picture:
    • Earnings are forecast to grow about 7.6% per year, which is below the Finnish market forecast of 13.2% per year, even though revenue is expected to grow around 8.2% compared with a 4.8% market benchmark.
    • At the same time, a DCF fair value of €155.84 and a P/E below the industry average both differ from the cautious view that expectations are too high, so the numbers do not line up neatly with a purely bearish stance.

Skeptics often focus on slower forecast earnings growth, but the detailed bear case also weighs pipeline risk, Nubeqa dependence and future capital needs, which are laid out clearly in the full cautious narrative 🐻 Orion Oyj Bear Case

Dividend, R&D push and €2.1b revenue base

  • On top of €2.1b in trailing revenue and €587.1 million in net income, Orion Oyj currently offers a 2.33% dividend yield while also increasing R&D and commercial spending around an oncology focused pipeline.
  • The balanced consensus narrative treats Orion as a company funding future cancer and specialty therapies from a solid base business, and the reported figures highlight both sides of that story:
    • Across the last six reported quarters, revenue has ranged between €354.6 million and €695.3 million, while basic EPS has moved between €0.44 and €1.85, so cash generation to support R&D and dividends comes from a fairly broad earnings base.
    • Pipeline metrics show 3 products in Phase I, 8 in Phase II and 6 in Phase III in Q2 2026, compared with smaller counts in early 2025, which aligns with the idea that more of Orion’s spend is being directed into oncology and specialty projects.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Orion Oyj on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both the bullish and cautious angles on Orion Oyj, do you feel the data supports the optimism? Act quickly, review the figures for yourself, and then weigh up the 4 key rewards.

See What Else Is Out There

Despite Orion Oyj’s high margins and progress in its cancer pipeline, the stock still faces questions related to its slower forecast earnings growth compared to the Finnish market, as well as ongoing pipeline risk.

If you are looking for ideas that may align more closely with your expectations on price and growth, take a look at the 226 high quality undervalued stocks to quickly scan other stocks that might fit your criteria before opportunities change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.